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Abstract 
Progression to clinical type 1 diabetes varies between children developing beta-cell 
autoantibodies. Differences in autoantibody patterns could relate to disease progression and 
etiology. Here we modeled complex longitudinal autoantibody profiles using a novel wavelet-
based algorithm. We identified clusters of similar profiles, associated with different types of 
progression, among 600 children from The Environmental Determinants of Diabetes in the 
Young birth cohort study who developed persistent autoantibodies against insulin (IAA), 
GAD (GADA) and/or insulinoma-associated antigen-2 (IA-2A), and were followed 
prospectively in 3 to 6 months intervals (median follow-up 6.5 years). Among multiple 
autoantibody-positive children (n=370), progression from seroconversion to clinical diabetes 
ranged between clusters from 6% (95%CI [0, 17.4]) to 84% (59.2, 93.6) within 5 years. 
Highest diabetes risks had children who seroconverted early in life (median age <2 years) and 
developed IAA and IA-2A that were stable-positive on follow-up, and these risks were 
unaffected by GADA status. Clusters lacking stable-positive GADA responses showed higher 
proportions of boys and lower frequencies of the HLA-DR3 allele. Our novel algorithm 
allows refined grouping of beta-cell autoantibody-positive children with distinct progression 
to clinical type 1 diabetes and provides new opportunities in searching for etiological factors 
and elucidating complex disease mechanisms. 
 
Page 3 of 38 Diabetes
4 
 
Clinical type 1 diabetes is commonly preceded by the development of autoantibodies against 
pancreatic beta-cell antigens such as insulin autoantibodies (IAA), GAD autoantibodies 
(GADA), insulinoma-associated antigen-2 autoantibodies (IA-2A), and zinc transporter 8 
autoantibodies (ZnT8A) (1). In particular, children who have developed two or more of these 
autoantibody types almost inevitably progress to clinically symptomatic diabetes (2). These 
findings have led to a new staging of type 1 diabetes, which classifies the presence of 
advanced beta-cell autoimmunity (multiple autoantibodies) in individuals without diabetic 
symptoms as an early stage of disease, i.e. presymptomatic type 1 diabetes (3,4). However, 
the time of progression from presymptomatic to clinical type 1 diabetes varies within multiple 
autoantibody-positive children (2). Autoantibody characteristics are known to stratify diabetes 
risk, including the age of seroconversion (2,5-7), antibody number (8-10), titer (6,7,9-12), 
affinity (13,14), antigen specificity (9,15-17) and epitope binding (9,14,18,19). Nevertheless, 
the relationship between various longitudinal autoantibody profiles and the rate of progression 
to diabetes remain yet rarely studied. The Environmental Determinants of Diabetes in the 
Young (TEDDY) study recently reported that among multiple autoantibody-positive children, 
those who reverted from GADA-positive to GADA-negative status on follow-up had greater 
diabetes risk than those with persistent autoantibodies (20). Likewise, clustering of children 
based on similarities between sequential autoantibody patterns in the German BABYDIAB 
cohort revealed delayed progression to type 1 diabetes in multiple autoantibody-positive 
children who became IAA-negative on follow-up (21). However, no study to date has 
analyzed longitudinal profiles of multiple autoantibodies in due consideration of the timing of 
changes in qualitative status of the different autoantibodies. 
The TEDDY study provides unique opportunities for the analysis of longitudinal autoantibody 
profiles based on whole time series of autoantibody sequences due to frequent sampling and 
measurements of type 1 diabetes-associated autoantibodies starting in early infancy (22). This 
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could refine stratification of progression to clinical diabetes based on similarities in the timing 
of changes in autoantibody responses. However, the high complexity and multivariate nature 
of the longitudinal autoantibody data remains a challenging task for analysis. To address this 
issue, we developed a mathematical algorithm based on Haar wavelet decomposition that 
enables clustering of children according to similarities in their longitudinal autoantibody 
profiles. In contrast to most published approaches (2,5-10,12,20), our proposed method does 
not require a priori definition of relevant autoantibody patterns or seroconversion ages but 
intrinsically groups children taking longitudinal characteristics into account. 
 
Research Design and Methods 
Study population and samples The TEDDY study is a prospective cohort study with the 
primary goal of identifying environmental causes of type 1 diabetes. It includes six clinical 
research centers, three in the USA (Colorado, Georgia/Florida, Washington) and three in 
Europe (Finland, Germany, Sweden). Detailed study design and methods have been published 
previously (22). TEDDY enrolled 8,676 children who are genetically at-risk for developing 
type 1 diabetes based on HLA genotypes (23). Children enrolled are monitored prospectively 
from age 3 months to 4 years with study visits every 3 months and thereafter every 3 or 6 
months until age 15 years, depending on autoantibody positivity. Children who are 
persistently positive for any autoantibody are monitored every 3 months until the age of 15 
years or onset of type 1 diabetes. If remission of all autoantibodies occurs for a period of 4 
consecutive visits or 1 year, an interval of 6 months becomes effective. Autoantibody-
negative children are monitored every 6 months. The study was approved by local 
Institutional Review or Ethics Boards and monitored by an External Evaluation Committee 
formed by the National Institutes of Health. All participants provided written informed 
consent before participation in the genetic screening and in the prospective follow-up. 
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As of 31 December 2014, 618 children had developed persistent confirmed beta-cell 
autoantibodies (IAA, GADA and/or IA-2A; 242 single autoantibody-positive, 376 multiple 
autoantibody-positive) during a median follow-up of 6.5 years (IQR 5.2-8.0 years), and 172 of 
those had developed diabetes. To avoid bias due to short follow-up profiles, all children with 
less than five longitudinal samples were excluded from the analysis (n=18). Thus, the current 
analysis included 600 children (230 single autoantibody-positive and 370 multiple 
autoantibody-positive), and 165 of those developed diabetes. We analyzed the qualitative 
status of IAA, GADA and IA-2A over time using 37,047 measurements from birth. 
 
Beta cell autoantibodies IAA, GADA, and IA-2A were measured in two laboratories by 
radiobinding assays, as previously described (22). In the U.S., all sera were assayed at the 
Barbara Davis Center for Childhood Diabetes at the University of Colorado Denver; in 
Europe, all sera were assayed at the University of Bristol, U.K. Both laboratories reported 
high sensitivity, specificity, and concordance (24). All positive beta-cell autoantibodies and 
5% of negative samples were retested in the other reference laboratory and deemed confirmed 
if concordant. Persistent beta-cell autoimmunity was defined as autoantibody presence on two 
or more consecutive visits 3 months apart and confirmed in two TEDDY laboratories. Age of 
seroconversion was defined as the age of the child on the initial date of seroconversion to 
persistent beta-cell autoimmunity, as previously described (25). A child was considered 
multiple autoantibody-positive if at least two autoantibodies of IAA, GADA and/or IA-2A 
were positive in two consecutive samples or if at least two of these autoantibodies were 
positive in the last available sample prior to the development of type 1 diabetes. An 
autoantibody response was defined as transiently positive if at least two consecutive samples 
were autoantibody-positive and then followed by at least two consecutive autoantibody-
negative samples or by an autoantibody-negative last available sample. An autoantibody 
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response was defined as stable-positive if it was not transiently positive. An autoantibody 
profile was defined as the qualitative status of IAA, GADA, IA-2A (i.e. positive/negative 
defined by cut-off) at a single time point, building a three-dimensional binary vector. A 
longitudinal autoantibody profile was defined as the temporal sequence of all single 
autoantibody profiles of a child. Type 1 diabetes was defined according to American Diabetes 
Association criteria for diagnosis (3). 
 
Statistical Analysis Based on binary longitudinal autoantibody profiles of IAA, GADA and 
IA-2A (i.e. temporal sequences of positive or negative autoantibody status of all children), we 
developed a mathematical algorithm using Haar wavelets (26) to quantify the similarity 
between longitudinal autoantibody profiles. Subsequently, hierarchical clustering was 
performed to group children based on similarities. Imputation of data was required whenever 
samples were missing in the sequence of autoantibody measurements. A missing sample was 
assigned autoantibody-positive if the last prior sample and the next subsequent sample were 
positive for the particular autoantibody. In all other cases, missing samples were assigned 
autoantibody-negative.  
Follow-up time and, accordingly, the number of available samples and autoantibody 
measurements varied considerably between children. We observed a bimodal distribution of 
follow-up time (Suppl. Fig. 1), with 82 children (69 multiple and 13 single autoantibody-
positive) being followed for up to 42 months and 518 children (301 multiple and 217 single 
autoantibody-positive) being followed for more than 42 and up to 122 months, respectively. 
Since only shared follow-up periods could be used for pairwise comparison of children, short 
periods that were shared between children with considerably different lengths of follow-up 
did not contain sufficient information to achieve reasonable clustering results based on 
wavelet coefficients alone, as children with qualitatively different longitudinal autoantibody 
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profiles could be clustered together. We therefore first grouped children with long (more than 
42 months) or short (up to 42 months) follow-up periods separately and later integrated the 
children with short follow-up into the clusters of children with long follow-up by using a 
combination of similarity of autoantibody patterns and similar timing of autoantibody 
development. 
At first, a Haar wavelet decomposition was applied to autoantibody sequences of children 
with more than 42 months of follow-up, separately for IAA, GADA, and IA-2A. The resulting 
wavelet coefficients of the three autoantibodies were then combined into a single vector. The 
latter was used to estimate Euclidean distances of wavelet coefficients between pairs of 
children. Hierarchical clustering with complete linkage was performed on the resulting 
distances, separately for multiple autoantibody-positive and single autoantibody-positive 
children, respectively. At second, children with shorter follow-up of up to 42 months were 
assigned to clusters of children with longer follow-up profiles by using a combination of 
distances based on wavelet coefficients and a recently described algorithm for measuring 
similarity between sequential autoantibody patterns (21). For both measures, a Student’s t 
statistic was calculated to compare the distances of children from each cluster to distances of 
children from all other clusters. Children with short follow-up were assigned to clusters of 
children with long follow-up with the maximum of the sum of both measures. The 
combination of distances from wavelet coefficients and from sequential autoantibody patterns 
ensured that children with short follow-up times were assigned to clusters with both similar 
timing of autoantibody appearance and similar longitudinal autoantibody profiles. 
Kaplan-Meier survival analysis with log-rank test was used to compare the progression from 
autoantibody seroconversion to type 1 diabetes between clusters. The time from the age of 
seroconversion to the age at diagnosis of diabetes or the age at last contact in non-diabetic 
children was used as event time. Analysis considered censoring for losses to follow-up. The 
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5-year diabetes-free survival is presented for clusters comprising 10 or more children. Fisher’s 
exact test was used to compare frequencies between groups. All statistical analyses were 
performed using R version 3.2.2. 
 
Results 
Clustering of multiple autoantibody-positive children We hypothesized that clustering of 
multiple autoantibody-positive children based on their consecutive profiles of IAA, GADA, 
and IA-2A could provide refined stratification with respect to progression to clinical type 1 
diabetes and disease etiopathogenesis, respectively. Clustering based on wavelet coefficients 
was performed for 370 children who developed multiple beta-cell autoantibodies. The 
resulting dendrogram (Fig. 1) was used to define 12 multiple autoantibody clusters (mC1-
mC12) comprising groups of 12 to 88 children who differed with respect to the age of 
autoantibody appearance and/or autoantibody profiles on follow-up (Fig. 2). Characteristics of 
the children in these clusters are summarized in Table 1. The clusters differed considerably 
with respect to the progression of children from seroconversion to clinical diabetes, ranging 
from 6% (95%CI [0, 17.4]; cluster mC9) to 84% (59.2, 93.6; mC5) within 5 years (Table 1). 
In particular, those clusters with the shortest distance to each other in the dendrogram (e.g. 
mC7 and mC8; Fig. 2) had markedly different diabetes-risks, indicating that the approach 
could distinguish children with different progression based on relatively small differences in 
their longitudinal autoantibody profiles. Next, we explored whether the clusters could stratify 
progression in children with common characteristics such as similar seroconversion age and 
autoantibody patterns. 
Children with seroconversion at very young age. First, we compared clusters of children with 
similar young age of seroconversion but variable longitudinal autoantibody profiles with 
respect to differences in their progression to clinical type 1 diabetes. We therefore selected all 
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clusters with median age of seroconversion <2 years. This resulted in six clusters (Fig. 3A) 
characterized by the development of either three stable-positive autoantibodies (cluster mC6), 
or two stable-positive autoantibodies in combination with a transiently positive or negative 
third autoantibody (clusters mC5, mC10, mC12), or stable-positive GADA (cluster mC11) or 
IA-2A (cluster mC3) in combination with a transiently positive or negative second and/or 
third autoantibody, respectively. Regardless of GADA status, children with the combination 
of stable-positive IAA and IA-2A (mC6 and mC5) had similar 5-year diabetes risks, being 
significantly higher than the risks in all remaining clusters of children with very young 
seroconversion age (P<0.0001, HR 2.8 (1.9-4.2); Fig. 3B, Table 1). In contrast, the 5-year 
diabetes risks were not significantly different between clusters of children with the 
combination of stable-positive GADA and IA-2A (mC10) or IAA and GADA (mC12) and 
those with just stable-positive GADA (mC11) or IA-2A (mC3), respectively (Fig. 3B, Table 
1). However, the overall frequency of diabetes throughout follow-up was higher in clusters 
with stable-positive IA-2A (mC10 [63%] and mC3 [50%]) as compared to those without 
(mC12 [32%] and mC11 [21%]; P=0.002; Fig. 3C). 
Children with similar autoantibody patterns. Second, we compared clusters of children with 
similar autoantibody patterns but variable age of seroconversion with respect to differences in 
their progression to clinical type 1 diabetes. We therefore grouped clusters based on 
autoantibody patterns over time, and then compared clusters within groups according to the 
median age of seroconversion at <2 years, 2-4 years and >4 years, respectively. This resulted 
in four groups of three clusters each (Fig. 4A, Suppl. Fig. 2A). Clusters were characterized by 
the development of either stable-positive IAA, GADA and IA-2A (clusters mC6, mC7, and 
mC2); stable-positive IA-2A and IAA, or, stable-positive IA-2A alone (clusters mC5, mC8, or 
mC3, respectively); stable-positive IA-2A and GADA (clusters mC10, mC9, mC4); or stable-
positive GADA and IAA, or stable-positive GADA alone (clusters mC12, or mC11, and mC1, 
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respectively). Within each cluster group, younger age at seroconversion was generally 
associated with increased 5-year diabetes risk (Fig. 4B-E); with the exception of children in 
cluster mC3 who seroconverted at median age <2 years, developed stable-positive IA-2A, but 
lost IAA reactivity on follow-up (Fig. 2, Fig. 4A) and presented with relatively delayed 
progression to clinical diabetes (Fig. 4C). The most significant effects of younger 
seroconversion age on diabetes risk were observed among children developing three stable-
positive autoantibodies (mC6 vs. mC7/mC2, P<0.0001, HR 5.4 [2.5-11.9]; Fig. 4B), those 
developing stable-positive IA-2A and IAA (mC5 vs. mC8, P=0.02, HR 2.3 [1.1-4.9]; Fig. 
4C), and those developing stable-positive IA-2A and GADA (mC10 vs. mC9/mC4, P=0.045, 
HR 3.9 [1.0-9.3]; Fig. 4D). Clusters of children with seroconversion at median age <2 years 
also showed higher overall frequencies of diabetes compared to those with similar 
autoantibody patterns but older seroconversion age (mC6 vs. mC7/mC2, P<0.0001; mC5 vs. 
mC8, P=0.007; mC10 vs. mC9/mC4, P<0.0001; Suppl. Fig. 2B). In contrast, the 5-year 
diabetes risks and overall diabetes frequencies were not statistically different between 
children who mainly lacked IA-2A and developed stable-positive GADA (mC12 vs. mC11 vs. 
mC1, P>0.05 for all pairwise comparisons; Fig. 4E, Suppl. Fig. 2B), and this was irrespective 
of seroconversion age. Of note, the differences in diabetes risk and overall diabetes frequency 
between clusters of multiple autoantibody-positive children were not explained by ZnT8A 
status (Suppl. Fig. 2C). 
Features associated with autoantibody patterns. Clusters lacking stable-positive GADA 
responses (clusters mC5, mC8, mC3) showed higher proportions of boys (P=0.002; Fig. 5A) 
and lower frequencies of the HLA-DR3 allele (P=0.0002; Fig. 5B) compared to all other 
multiple autoantibody clusters. 
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Clustering of single autoantibody-positive children To analyze characteristics associated 
with different patterns of autoantibody reactivity against single beta-cell antigens, 230 single 
autoantibody-positive children were clustered based on wavelet decomposition of longitudinal 
time series of IAA, GADA, and IA-2A. The resulting dendrogram (Suppl. Fig. 3) was used to 
define nine single autoantibody clusters (sC1-sC9) containing groups of 5 to 50 children who 
differed with respect to their longitudinal autoantibody profiles (Suppl. Fig. 4). Characteristics 
of the children in these clusters are summarized in the online appendix (Suppl. Table 1). 
Children with stable-positive GADA responses were clustered into two groups (clusters sC1 
and sC2) that differed with respect to the age of seroconversion (P<0.0001; Suppl. Table 1) 
but had similar 5-year diabetes risks (Suppl. Fig. 5A,B). Compared to clusters sC1 and sC2 
combined, significantly increased 5-year diabetes risk was observed for cluster sC5 consisting 
of children with stable-positive IAA (P=0.008, HR 4.3 [1.3-13.5]; Suppl. Table 1, Suppl. Fig. 
5A,B). None of the children in clusters characterized by either transiently positive GADA 
(clusters sC3 and sC6) or IAA (clusters sC7, sC8, sC9) developed diabetes on follow-up 
(Suppl. Table 1, Suppl. Fig. 5A,B). Clusters of children with transiently positive IA-2A were 
not observed. 
Differences were seen in positivity for ZnT8A between clusters (Suppl. Table 1, Suppl. Fig. 
5C). While 80% (4 of 5) of children in the small cluster sC4 (stable-positive IA-2A) 
developed ZnT8A, only 37% (15 of 41) and 12% (4 of 33) of children in clusters sC1 and sC2 
(stable-positive GADA), and 10% (2 of 21) of children in cluster sC5 (stable-positive IAA) 
developed ZnT8A, respectively. 
HLA genotype was associated with single autoantibody clusters. Of note, HLA DR3-
DQ2/DR3-DQ2 was absent in clusters of children with stable-positive IA-2A (sC4) or IAA 
(sC5). In contrast, HLA DR3-DQ2/DR3-DQ2 was relatively frequent among clusters of 
children with stable-positive GADA (sC1 38%, sC2 24%) or transiently positive GADA (sC3 
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44%, sC6 24%; Suppl. Table 1, Suppl. Fig. 5D). Clusters with stable-positive GADA (sC1 
and sC2) showed increased frequencies of the HLA-DR3 allele compared to clusters with 
stable-positive IAA (sC5, P=0.003; Suppl. Fig. 5D) or IA-2A (sC4, P=0.05; Suppl. Fig. 5D), 
respectively. 
 
Discussion 
In the current study, we have tackled the challenge of combined analysis of complex 
longitudinal profiles of multiple biomarkers, namely three different types of beta-cell 
autoantibodies, in a time-resolved fashion. Specifically, we considered the age and sequence 
of changes in the qualitative status (i.e. positive or negative) of each autoantibody in each 
serum sample collected throughout follow-up of 600 children who developed persistent 
confirmed IAA, GADA and/or IA-2A while participating in the TEDDY study, comprising 
more than 37,000 antibody measurements. Using a novel wavelet-based algorithm we were 
able to define similarities between the longitudinal autoantibody profiles of children, 
including the temporal resolution of changes in autoantibody patterns. Based on these 
similarities, we could then perform hierarchical clustering of single and multiple 
autoantibody-positive children to define clusters that were associated with markedly different 
progression rates from seroconversion to clinical diabetes, particularly among those children 
with multiple autoantibodies, ranging from 6% to 84% within 5 years. Furthermore, we could 
pinpoint specific autoantibody patterns and characteristics related to different progression 
rates. We suggest that our approach holds great potential for refined explorations into the 
underlying etiology of different phenotypes of beta-cell autoimmunity. 
Strengths of our study include the unique and well-defined cohort, and the use of an 
innovative analytical approach. The TEDDY study is the largest prospective study to date that 
follows genetically at-risk children for the development of beta-cell autoimmunity and type 1 
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diabetes (22). TEDDY has collected various possible exposures that could be important to the 
appearance and progression of beta-cell autoimmunity (27-32). Associations with genetic risk 
factors and age of appearance, type and levels of beta-cell autoantibodies, and progression to 
clinical type 1 diabetes have recently been reported (7,20,25,33-35). This current analysis 
adds to these previous studies in a new manner in that our novel approach is data-driven and 
considers changes in autoantibody characteristics at the time they occur. 
We made use of Haar wavelet coefficients (26) to define similarities between longitudinal 
profiles of children. This approach holds a number of advantages for the analysis of 
prospective study data. However, it has not yet been used in prospective studies in type 1 
diabetes. Wavelets enable a time-frequency type decomposition of time series data. Applying 
an iterative scheme, coefficients determined at the earlier steps capture ‘high-frequency’ 
information in the data such as on-and-off switches, whereas coefficients at later iteration 
steps allow identifying long-term trends in time series data. Wavelets are therefore a powerful 
tool to characterize dynamic temporal patterns in autoantibody progression. Still, intrinsic 
characteristics of the method need to be considered. Firstly, using Haar wavelets (i.e. a 
decomposition based on piecewise constant functions) might not provide the best orders of 
approximation, while at the same time being computationally very efficient. Nevertheless, for 
the type of data analyzed in this study, Haar wavelet coefficients turned out to capture the 
information well enough and no wavelets with higher order moments were needed. Secondly, 
in order to compare longitudinal autoantibody profiles of children, time series of differing 
lengths had to be cut down to the length of the shorter series. Thus, in particular when 
comparing a very short time series with a longer one, the comparison based on wavelets 
ignores a substantial part of the information provided by the longer series. We compensated 
for this deficiency in our analysis by combining wavelet decomposition with another 
qualitative algorithm provided previously (21). Thirdly, the method also requires that time 
Page 14 of 38Diabetes
15 
 
series have to be sampled equidistantly. While this is the case in the TEDDY study, other 
decompositions would have to be applied for scattered data. 
We have focused our analysis on the group of multiple beta-cell autoantibody-positive 
children. Considerable differences exist between children at this presymptomatic stage of type 
1 diabetes with respect to the time until clinical disease onset (2,7,36). A well-known risk 
factor for faster progression to clinical diabetes among autoantibody-positive individuals is 
young age of seroconversion (5-7,34). It is therefore remarkable that we could a) distinguish 
different rates of progression among clusters of multiple autoantibody-positive children 
(n=217) who all seroconverted at very young age, and b) link differences in progression to 
defined longitudinal autoantibody profiles. The highest risks were seen in 115 children who 
developed both stable-positive IAA and IA-2A responses early in life (clusters mC6 and 
mC5). Interestingly, high risk in those children was not influenced by the presence (mC6) or 
absence (mC5) of stable-positive GADA responses. On the contrary, risk was significantly 
lower for 102 children who seroconverted early and developed multiple autoantibodies but 
not stable-positive IAA and IA-2A. This is in line with our previous observation in the 
BABYDIAB cohort that losing IAA reactivity is associated with delayed progression to type 
1 diabetes in multiple autoantibody-positive children (21). Amongst clusters of children with 
similar autoantibody patterns, younger age of seroconversion was associated with faster 
progression rate. An exception to this rule were children who developed stable-positive 
GADA but lacked IA-2A responses, and progressed relatively slowly regardless of 
seroconversion age. 
Of note, in order to develop an autoantibody response to GAD that was stable-positive over 
time and, therefore, presumably relevant for the individual immune phenotype and disease 
pathogenesis, the majority of those children appeared to require HLA-DR3. Associations 
between HLA-DR and beta-cell autoantibody specificity have been reported (13,14,25,37-39). 
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In particular, the TEDDY study has recently demonstrated that the appearance of either IAA 
or GADA as the first autoantibody in children was strongly influenced by the presence of 
HLA-DR4 or, respectively, HLA-DR3 (25,35). Our current data suggest an influence of HLA 
genotype on longitudinal autoantibody profiles. Likewise, male sex has been associated with 
IAA only as the first autoantibody in children (35). We have observed now a predominance of 
boys for longitudinal autoantibody profiles lacking stable-positive GADA responses, which 
requires further attention. 
As limitation to our study, longitudinal ZnT8A profiles could not be included in the current 
clustering analyses due to incomplete time series of ZnT8A measurements, which otherwise 
would have caused considerable reduction in sample size. However, we considered the overall 
ZnT8A status of each child in our analysis. As expected, this revealed that some children in 
the ‘single’ autoantibody clusters in fact had developed ZnT8A as second positive beta-cell 
autoantibody. The strongest effect was seen in the small cluster sC4, characterized by stable-
positive IA-2A, in which four of five children (all male, carrying HLA-DR4) were ZnT8A-
positive and two have progressed to clinical diabetes. This illustrates that certain low 
frequency immune patterns could be highly disease-relevant. With respect to longitudinal 
GADA patterns our study in children could underestimate their effect on diabetes-risk given 
that GADA is associated with older onset type 1 diabetes (40). Another limitation is that the 
study population is highly selected for HLA-conferred risk of type 1 diabetes (23). Validation 
in a study population that is not preselected, and cohorts of individuals seroconverting to beta-
cell autoantibodies at older age is therefore necessary to ensure wider applicability of our 
observations. 
Altogether, our data support the notion that the individual pattern of beta-cell autoantibodies, 
i.e. the pattern of main target autoantigens, as well as the timing of their appearance, dynamic 
and progression to diabetes is influenced by gene-environmental interactions. It is possible 
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that certain disease-promoting factors or conditions could act on genetically predisposed 
individuals only within certain age windows. Identifying such etiological factors could 
potentially pave the way for new prevention therapies, and we believe that our analytical 
approach could prove useful in that search. 
In conclusion, our novel wavelet-based clustering algorithm allows refined grouping of 
multiple beta-cell autoantibody-positive children. The data-driven approach can identify 
groups of children with distinct progression to clinical type 1 diabetes and provides new 
opportunities in elucidating complex disease mechanisms. 
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Table 1. Distribution of features among the multiple autoantibody clusters (mC1-mC12). 
 
T1D, type 1 diabetes; C-Section, Caesarean section; IQR, interquartile range. 
Autoantibody Cluster all mC1 mC2 mC3 mC4 mC5 mC6 mC7 mC8 mC9 mC10 mC11 mC12 
N 370 35 30 12 21 27 88 27 24 16 30 19 41 
Age (years) of seroconversion 
median (IQR) 
2.0 
(1.1-3.1) 
4.0 
(3.0-4.7) 
4.2 
(2.8-5.5) 
1.0 
(0.8-2.0) 
7.2 
(3.3-7.5) 
1.0 
(0.8-1.1) 
1.4 
(0.8-1.8) 
3.3 
(3.0-3.9) 
2.4 
(1.8-2.9) 
2.5 
(2.3-3.0) 
1.7 
(1.0-2.2) 
1.6 
(1.1-2.0) 
1.5 
(1.0-2.3) 
T1D prevalence (%) 41 11 17 50 14 85 66 7 46 12 63 21 32 
5-year T1D risk 
% (95% CI) 
44 
(38-49) 
12 
(0-23) 
28 
(0-49) 
51 
(5-75) 
26 
(0-49) 
84 
(59-94) 
63 
(51-72) 
9 
(0-21) 
53 
(21-72) 
6 
(0-17) 
41 
(20-57) 
22 
(0-39) 
40 
(19-56) 
Maternal T1D (%) 6 14 10 8 0 7 5 4 4 6 3 0 5 
HLA DR3/DR3 (%) 7 9 3 8 5 0 3 4 0 31 17 21 7 
HLA DR3/DR4 (%) 57 69 63 33 48 44 64 56 38 56 43 68 63 
HLA DR4/DR4 (%) 18 17 23 33 14 15 10 26 42 13 27 0 15 
HLA DR4/DRx 18 6 10 25 33 41 22 15 21 0 13 11 15 
ZnT8A (%) 62 51 73 83 52 44 58 74 71 75 77 47 56 
C-Section (%) 22 26 20 50 24 37 17 26 17 25 20 16 20 
Male (%) 56 57 50 83 52 74 55 52 67 69 50 47 41 
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Figure Legends 
Figure 1. Hierarchical clustering results for longitudinal autoantibody profiles of 370 children 
who developed multiple beta-cell autoantibodies. The dendrogram is divided into 12 multiple 
autoantibody clusters (mC1-mC12). Each column represents the follow-up time from birth for 
one child. The qualitative status of IAA, GADA and IA-2A, respectively, is indicated by color 
(red = antibody-positive; blue = antibody-negative) with respect to the age at antibody 
measurement. 
 
Figure 2. Aggregated longitudinal profiles of IAA, GADA, and IA-2A are shown for children 
of multiple autoantibody clusters (mC1-mC12). For each cluster, the percentage of children 
positive for the respective autoantibody is indicated by color (white: 0% positive; red: 100% 
positive) with respect to age. The blue and green lines indicate the age until which >50% and 
>25% of children in the cluster were followed, respectively. Autoantibody profiles are plotted 
until only two children in the cluster remained in follow-up. 
 
Figure 3. Characteristics of clusters of multiple autoantibody-positive children with 
seroconversion at very young age (median age <2 years). For each cluster is shown: (A) the 
percentage of children who were stable-positive, transiently positive, or negative on follow-up 
for IAA, GADA and IA-2A, respectively; (B) the cumulative diabetes-free survival from 
autoantibody seroconversion; (C) the overall frequency of diabetes throughout follow-up. 
 
Figure 4. Progression to type one diabetes among clusters of multiple autoantibody-positive 
children with similar autoantibody characteristics but variable age of seroconversion. Clusters 
are grouped into four groups of three clusters each, based on similarity of autoantibody 
profiles. For clusters of each group is shown: (A) the percentage of children who were stable-
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positive, transiently positive, or negative on follow-up for IAA, GADA and IA-2A, 
respectively; (B-E) the cumulative diabetes-free survival from autoantibody seroconversion. 
 
Figure 5. The proportions of boys (A) and HLA-DR genotypes (B) are shown for multiple 
autoantibody clusters (mC1-mC12) grouped into four groups of three clusters each, based on 
similarity of autoantibody profiles. The cluster group mC5, mC8, mC3 comprised a 
significantly higher proportion of boys (P=0.002) and lower frequency of HLA-DR3 
(P=0.0002) compared to the other cluster groups. 
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Supplementary Table 1. Distribution of features among the single autoantibody clusters (sC1-sC9). 
T1D, type 1 diabetes; C-Section, Caesarean section; IQR, interquartile range. 
Autoantibody Cluster all sC1 sC2 sC3 sC4 sC5 sC6 sC7 sC8 sC9 
N 230 41 33 9 5 21 50 26 27 18 
Age (years) of seroconversion 
median (IQR) 
3.5 
(1.8-5.1) 
3.1 
(2.3-3.7) 
5.2 
(5.0-6.0) 
3.5 
(3.3-3.8) 
4.4 
(3.3-4.8) 
2.1 
(1.3-3.3) 
5.9 
(2.0-7.7) 
1.8 
(1.0-4.6) 
4.5 
(1.9-5.7) 
3.1 
(2.5-4.0) 
T1D prevalence (%) 7 12 3 0 40 33 0 0 0 0 
5-year T1D risk 
% (95% CI) 
10 
(4-15) 
12 
(0-24) 
3 
(0-90) 
- 
- 
- 
- 
46 
(10-68) 
0 
(0-0) 
0 
(0-0) 
0 
(0-0) 
0 
(0-0) 
Maternal T1D (%) 4 5 3 0 20 5 4 4 0 6 
HLA DR3/DR3 (%) 21 38 24 44 0 0 24 12 7 18 
HLA DR4/DR3 (%) 42 43 45 33 40 52 34 54 44 29 
HLA DR4/DR4 (%) 18 13 15 11 40 19 26 12 26 0 
HLA DR4/DRx 20 8 15 11 20 29 16 23 22 53 
ZnT8A (%) 14 37 12 0 80 10 6 15 0 6 
C-Section (%) 26 27 30 44 40 24 26 15 22 22 
Male (%) 57 49 70 44 100 62 62 65 52 22 
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Supplementary Figure 1. Distribution of follow-up time of 600 children who developed persistent beta cell 
autoimmunity. Density is plotted for age of last available follow-up serum sample among all follow-up samples 
of all children. A vertical red line is drawn at age 42 months, separating two groups of children with short and 
long follow-up time, respectively.
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Supplementary Figure 2. Multiple autoantibody clusters (mC1-mC12) are grouped into four groups of three clusters each, based 
on similarity of autoantibody patterns over time. For clusters of each group is shown: (A) the age of seroconversion (median 
[quartiles]); (B) the overall frequency of diabetes throughout follow-up; (C) the percentage of children who were ZnT8A-positive on 
follow-up.
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Supplementary Figure 3. Hierarchical clustering results for longitudinal autoantibody profiles of 230 children who developed single 
beta cell autoantibodies. The dendrogram is divided into 9 single autoantibody clusters (sC1-sC9). Each column represents the 
follow-up time from birth for one child. The qualitative status of IAA, GADA and IA-2A, respectively, is indicated by color (red = 
antibody-positive; blue = antibody-negative) with respect to the age at antibody measurement.
Page 34 of 38Diabetes
1 3 5 7 9
IA-2A
GADA
IAA
1 3 5 7 9
IA-2A
GADA
IAA
1 3 5 7 9
IA-2A
GADA
IAA
1 3 5 7 9
IA-2A
GADA
IAA
1 3 5 7 9
IA-2A
GADA
IAA
1 3 5 7 9
IA-2A
GADA
IAA
1 3 5 7 9
IA-2A
GADA
IAA
1 3 5 7 9
IA-2A
GADA
IAA
1 3 5 7 9
IA-2A
GADA
IAA
sC1 (N=41)
Age (years)
sC2 (N=33)
Age (years)
sC3 (N=9)
Age (years)
sC4 (N=5)
Age(years)
sC5 (N=21)
Age(years)
sC6 (N=50)
Age (years)
sC7 (N=26)
Age (years)
sC8 (N=27)
Age (years)
sC9 (N=18)
Age (years)
0 20 40 60 80 100
% autoantibody positive
Probes available 
for > 25% of samples
Probes available 
for > 50% of samples
Supplementary Figure 4. Aggregated longitudinal profiles of IAA, GADA, and IA-2A are shown for children of single autoantibody 
clusters (sC1-sC9). For each cluster, the percentage of children positive for the respective autoantibody is indicated by color 
(white: 0% positive; red: 100% positive) with respect to age. The blue and green lines indicate the age until which >50% and >25% 
of children in the cluster were followed, respectively. Autoantibody profiles are plotted until only 2 children in the cluster remained 
in follow-up.
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